ATRC

Based on AtriCure, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.

What does AtriCure do?

AtriCure develops and sells surgical devices used to treat atrial fibrillation and manage post-operative pain. Its product line includes radiofrequency ablation clamps, cryoablation systems, and left atrial appendage closure devices sold to hospitals and surgical centers in the US and internationally.

Does ATRC pay dividends?

No, AtriCure does not pay a dividend. The company reinvests available capital into product development, clinical evidence generation, and geographic expansion — a common approach for growth-stage medical device companies that have not yet reached sustained profitability.

When does ATRC report earnings?

AtriCure follows a standard quarterly earnings cadence for US-listed companies. For precise dates, check AtriCure's investor relations page, where the company posts its earnings calendar and press releases.

Is ATRC a good stock to buy?

UQS Score rates ATRC as Below Average overall. While the Growth and Risk pillars show relative strengths, the Weak Quality and Moat ratings highlight meaningful concerns. Whether ATRC fits your portfolio depends on your risk tolerance and investment thesis — the full pillar breakdown is available to Pro members.

Is ATRC overvalued?

The UQS Valuation pillar for ATRC is rated Neutral, suggesting the current price is neither clearly discounted nor obviously stretched relative to the company's fundamentals. Investors should weigh this alongside the Weak Quality and Moat ratings when forming a view.

How does ATRC compare to its competitors?

AtriCure competes in a niche segment of the medical device market. Compared to peers like NovoCure, Pulse Biosciences, and Kestra Medical, AtriCure is more narrowly focused on cardiac surgical ablation and appendage closure. See the UQS competitor comparison for a side-by-side quality score view.

What is ATRC's market cap bracket?

AtriCure is classified as a small-cap company. This places it in a segment of the market that can offer growth potential but often carries higher volatility and less analyst coverage than large- or mega-cap peers.

Who founded AtriCure?

AtriCure was founded in 2005. Founding details, including the names of its founders, are publicly available through the company's official history and SEC filings for those researching its origins.

Is ATRC a long-term quality investment?

As a long-term quality indicator, ATRC's Below Average UQS Score reflects current weaknesses in Quality and Moat that may limit compounding potential over time. The Good Growth rating offers some optimism, but durable long-term quality typically requires stronger profitability and competitive positioning than ATRC currently demonstrates.

What is the main competitive advantage of AtriCure?

AtriCure's primary advantage lies in its specialized focus on surgical cardiac ablation and left atrial appendage management — a niche with limited direct competition. However, the UQS Moat pillar is rated Weak, suggesting this advantage has not yet translated into the kind of durable pricing power or switching costs seen in higher-rated peers.

What sector does ATRC belong to?

AtriCure operates in the Healthcare sector, specifically within the medical devices and equipment segment. It targets cardiac surgery suites and electrophysiology labs, making it sensitive to hospital capital spending trends and clinical reimbursement policies.

AtriCure, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.

AtriCure, Inc. is growing rapidly with strong revenue and earnings expansion.

AtriCure, Inc. carries minimal financial risk with conservative leverage and strong solvency.

AtriCure, Inc. has a mixed valuation — some metrics suggest fair value while others appear stretched.

AtriCure, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ATRC.

The UQS (Unified Quality Score) for AtriCure, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses AtriCure, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether AtriCure, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.